Skip to content

The non-inferiority trial of all-inside arthroscopic treatment of Hepple III osteochondral lesion of the talus combined with Jintiange versus sodium hyaluronate

Prospective, randomized controlled clinical trial to evaluate the safety and clinical effect of Jintiange in patients with Hepple III osteochondral lesion of the talus

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066571
Enrollment
Unknown
Registered
2022-12-09
Start date
2022-12-09
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepple III osteochondral lesion of the talus

Interventions

J Group:Give Jintiange capsule orally
S Group:Intraarticular injection of sodium hyaluronate

Sponsors

Xuzhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) At least 20 years old. (2) X-ray film or CT scan showed the damage of talus cartilage, and the type of damage was Hepple III talus cartilage injury. (3) The damage and relaxation of ATFL were confirmed by preoperative ultrasound imaging, MRI and intraoperative microscopy. (4) The front drawer test of ankle joint was positive. (5) Willing to undergo arthroscopic surgery

Exclusion criteria

Exclusion criteria: (1) Combined with other combined injuries. (2) Previous mechanical instability of the lateral ankle joint. (3) Can not tolerate surgery, with severe organic disease or. (4) The local skin condition is poor and can not tolerate arthroscopic surgery. (5) Those over 65 years old.

Design outcomes

Primary

MeasureTime frame
visual analogue scale;American Orthopedic Foot and Ankle Society scoring system;Karlsson Ankle Functional Score scoring system;Anterior Talar Translation;Active Joint Position Sense;

Secondary

MeasureTime frame
foot ankle outcomes scoring system;foot ankle outcomes scoring system;

Countries

China

Contacts

Public Contactshi-ming feng

Xuzhou Central Hospital

fengshiming_04@163.com18112007527

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026